Different types of interferon for the therapy of HCV chronic active hepatitis in the elderly patient

R Terranova1, S Luca

  • 1Department of Geriatrics and Gerontology, University of Catania, Italy.

Insights

Hepatitis C virus (HCV) correlated hepatitis in older adults shows recombinant interferon alpha is the most effective treatment. Despite potential side effects, its higher remission rate makes it the preferred choice for elderly patients.

Area of Science:

  • Hepatology
  • Virology
  • Geriatric Medicine

Background:

  • Hepatitis C virus (HCV) correlated hepatitis is increasingly prevalent in individuals over 60.
  • Current treatment options for this demographic are limited, primarily involving interferon therapy.

Purpose of the Study:

  • To compare the efficacy and safety of three interferon types for treating HCV-correlated chronic hepatitis in the elderly.
  • To determine the optimal interferon therapy for older patients based on remission rates and side effect profiles.

Main Methods:

  • Review and analysis of three previous studies involving recombinant interferon alpha, interferon beta, and lymphoblastoid interferon.
  • Evaluation of patient remission percentages and reported side effects in elderly populations.

Main Results:

  • Recombinant interferon alpha demonstrated the highest remission rate at 75%.
  • Interferon beta achieved a 53.8% remission rate, while lymphoblastoid interferon showed 60%.
  • Beta-interferon exhibited minimal side effects in elderly patients.

Conclusions:

  • Recombinant interferon alpha is the preferred treatment for HCV-correlated chronic hepatitis in the elderly due to superior efficacy.
  • Despite a potentially higher risk of side effects, the risk/benefit ratio favors recombinant interferon alpha for this patient group.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...